Fifty eight children with Langerhans celi histiocytosis who were referred to this hospital between 1980 and 1987 were studied. Fourteen had single system disease, and 44 had multisystem disease, of whom 22 had vital organ dysfunction. A conservative approach to treatment was adopted, and when systemic treatment was indicated a short course of prednisolone was used first. Eight of the patients with single system disease required no treatment, while six received local treatment alone. Eight of the patients with multisystem disease did not require systemic treatment, 17 were given prednisolone alone, and 19 were given cytotoxic drugs. Of the 14 with single system disease 13 had no long term after effects. Eight of the patients with multisystem disease died, 24 had long term after effects, and 12 had none. Outcome was related to age and Lahey score.
Langerhans cell histiocytosis is a rare disease and all the previous large studies have included patients presenting over several decades,' patients seen at several centres,2 or both.3 There is a wide variation in classification and treatment of patients among centres, and supportive treatments (such as antibiotics) change with time and tend to improve results. Historically, Langerhans cell histiocytosis was regarded as malignant and treated with increasingly aggressive regimens of chemotherapy. It is now generally considered to be reactive and flow cytometric studies support this view. 4 Langerhans cell histiocytosis presents in different ways, and there is, as yet, no uniformly accepted classification system of extent of disease. This, combined with its rarity, means that few adequate comparative treatment studies have been carried out. At this hospital a conservative approach has been adopted since 1980. Single system bony disease is treated where possible with curettage or injection of steroids into the lesion. Multisystem disease is treated only if there is evidence of constitutional upset (fever, pain, immobility), failure to thrive or worsening disease in vital organs. Pulsed high dose prednisolone is given first, in a dose of 2 mg/kg/day for a month, and then tailed off over a two month period. 
TREATMENT
Of the patients with single system disease, eight had no treatment apart from a diagnostic biopsy. One was given radiotherapy, four had operations (excision of a skin plaque (n= 1), curettage of bone lesions (n=2), and laminectomy (n= 1)), and one had steroid injected into the lesion.
Of the 44 patients with multisystem disease, five had no treatment, one had topical mustine alone to the skin, and two had radiotherapy alone. Of 36 children treated with prednisolone, 21 also required cytotoxic drugs.
OUTCOME
Of the 14 children with single system disease, one who had radiotherapy in 1981 now has a minor periorbital deformity, but 13 have no after effects.
Of the 44 with multisystem disease, eight (two girls and six boys) died (18%); all the children who died had been less than 2 years old at presentation, had developed vital organ dysfunction, and died within two years of pre- sentation. The male:female ratio among the deaths corresponded roughly to the ratio in the whole group. Table 1 shows the outcome and age at presentation, and table 2 is a life table of survival after diagnosis. Figure 1 shows the age related mortality in our series compared with those published in Lahey's first paper.2 The Lahey series may, however, include patients who would not be considered to have Langerhans cell histiocytosis using present diagnostic criteria. Comparison of actuarial rather than crude survival rates would have been preferable but this information is not given in other series. Table 3 shows the percentage surviving in the present series, and the Dutch-Austrian-German histiocytosis X(DAL-HX)8 and the AEIOP studies,9 divided according to the presence or absence of vital organ dysfunction. These show that our mortality is no worse than in these other European trials in which more aggressive and prolonged treatment was used. Toogood et al reported the results of aggressive chemotherapy in 25 children, of whom 13 would have been defined by us as having multisystem disease, including five with vital organ dysfunction.1' Five children (38%) died of overwhelming sepsis, including two in whom only bone and gingiva were affected, and who would have been unlikely to be given systemic treatment at our centre.
Twelve patients with multisystem disease (including six of the eight who were not given systemic treatment) had no long term after effects. Four had orthopaedic abnormalities alone, nine had endocrine dysfunction alone, one had hearing deficit alone, one had liver fibrosis alone, and nine had more than one of the above. Sixteen patients (36%) had diabetes insipidus, which in 11 patients was associated with other disease related morbidity. In all cases chronic morbidity was the result of the disease rather than of its treatment.
The maximum Lahey score was highly significantly related to both outcome score (p<OOOl) and number of courses of treatment (p<OOOOl). There was no significant association between Lahey score at presentation and either of these outcome measures. Figure 2 shows the mortality and maximum Lahey score compared with those in previously reported series.
Discussion
A child who dies of Langerhans cell histiocytosis usually does so within two years of diagnosis, either from the disease or complications of treatment." Of the 36 patients with multisystem disease in our series diagnosed more than two years before the analysis, seven have died. Of the eight more recently diagnosed patients still at risk, one has died; this gives an overall mortality of 14%, or 36% of patients with organ dysfunction. All eight children died of progressive Langerhans cell histiocytosis, none died of the complications of treatment. Survival for the whole group of 86% compares favourably with series of children treated more aggressively with combination chemotherapy for much longer periods (table 3, figs 1 and 2).
All authors agree that children under 2 years of age who present with multisystem soft tissue disease and vital organ dysfunction as defined by Lahey have the highest mortality. The aim of treatment in these patients is to reduce this mortality, but there is no evidence that this goal is being achieved by more aggressive chemotherapy.'0 The change in concept of the disease to a 'reactive condition' rather than cancer suggests the need for immune modulation rather than intensification of chemotherapy in the future.
The survival of all our patients with single system disease is not unusual, but it is noteworthy that this has been achieved with minimal intervention-presumably an advantage to patients. Morbidity in our series was confined to patients with multisystem disease, apart from one child with single system periorbital bony disease who was left with a minor facial deformity. Twenty four of 36 survivors had some after effects, and this is comparable with other studies such as those of Lahey2 and Sims,' in which more aggressive continuous treatment was used. The rate of diabetes insipidus in our group (36% of those with multisystem disease) was similar to the 35% in Sims's study' and four of 13 (31%) in the series reported by Toogood et al,'°but is in contrast to the 18% in the AEIOP study, and 4% in the DAL-HX study. This may reflect referral bias in our patients, or a higher percentage of patients in our series with extensive disease and higher Lahey scores. Alternatively, it may be a true consequence of our less intensive treatment. Further studies are needed, however, to determine whether aggressive or maintenance treatment prevents the development of diabetes insipidus.
There is no suggestion to date that aggressive chemotherapy prevents other long term after effects. It may, however, be both myelosuppressive and immunosuppressive, and previous regimens of chemotherapy were associated with at least a 5% risk of inducing malignancy in the long term. 3 Comparing morbidity and mortality among series is hampered by the lack of uniformly accepted methods for evaluation of the extent of disease, and of the response to treatment. A working group of the Histiocyte Society is currently studying this question. With a 'common language' the way would be open for both useful comparisons and international studies, preferably randomised. Until that time we suggest that those caring for patients with Langerhans cell histiocytosis should consider a conservative, rather than an aggressive, approach. Nevertheless, it is critical that initial referral should be to a major centre with a commitment to clinical and basic research in Langerhans cell histiocytosis. Centralisation of tissue and data should advance the day when the mechanism of the disease is understood and rational treatment designed. 'Shared care' arrangements can and should be made when long distance referral is necessary.
